Psoriasis hastalığında çölyak hastalığı antikorlarını inceledik. Çalışmamız Annals of Dermatology dergisinde yayınlandı. Özetlemek gerekirse, antigliadin IgA psoriasis hastalarında kontrol grubuna göre istatistiksel olarak anlamlı yüksek saptandı.
Tam metin okumak isteyen lütfen çekinmesin.
Referans:Akbulut S, Gur G, Topal F, Senel E, Topal FE, Alli N, Saritas U. Coeliac disease-associated antibodies in psoriasis. Annals of Dermatology. Ann Dermatol. 2013 Aug;25(3):298-303.
Özet:Background: The possible relationship between psoriasis and coeliac disease (CD) has been attributed to the common pathogenic mechanisms of the two diseases and the presence of antigliadin antibodies in patients has been reported to increase the incidence of CD. Objective: The aim of this report was to study CD-associated antibodies serum antigliadin antibody immunoglobulin (Ig)A, IgG, anti-endomysial antibody IgA and anti-transglutaminase antibody IgA and to demonstrate whether there is an increase in the frequency of those markers of CD in patients with psoriasis. Methods: Serum antigliadin antibody IgG and IgA, antiendomysial antibody IgA and anti-transglutaminase antibody IgA were studied in 37 (19 males) patients with psoriasis and 50 (23 males) healthy controls. Upper gastrointestinal endoscopy and duodenal biopsies were performed in patients with at least one positive marker. Results: Antigliadin IgA was statistically higher in the psoriasis group than in the controls (p＜0.05). Serological markers were found positive in 6 patients with psoriasis and 1 person from the control group. Upper gastrointestinal endoscopy was performed in all these persons, with biopsies collected from the duodenum. The diagnosis of CD was reported in only one patient with psoriasis following the pathological examination of the biopsies. Whereas one person of the control group was found to be positive for antigliadin antibody IgA, pathological examination of the duodenal biopsies obtain from this patient were found to be normal. Conclusion: Antigliadin IgA prominently increases in patients diagnosed with psoriasis. Patients with psoriasis should be investigated for latent CD and should be followed up. (Ann Dermatol 25(3) 298∼303, 2013)